Skip to main content
hello world

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

iTeos Provides Clinical Development Plans and Promotes Yvonne McGrath, Ph.D. to Chief Scientific Officer

Globe Newswire - Mon Jan 10, 2022

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Jan. 10, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today provided a clinical development plan for its anti-TIGIT monoclonal antibody, EOS-448, and its A2A receptor antagonist, inupadenant. iTeos also announced the promotion of Yvonne McGrath, Ph.D., to chief scientific officer.

Read more at globenewswire.com